Increased plasma fibrinolytic activity in bleeding gastrointestinal angiodysplasia

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 2, 2005, Pages 199-205

  Junquera, Félix ^a   Saperas, Esteban ^a   Anglés, Ana ^a   Abadía, Carmen ^a   Monasterio, Jasone ^a   Malagelada, Juan Ramón ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Angiodysplasia; Bleeding; Hyperfibrinolysis; Plasminogen activator inhibitor type 1

Indexed keywords

BLOOD CLOTTING FACTOR 7A; D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIODYSPLASIA; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DUODENUM ULCER; FEMALE; FIBRINOLYSIS; GASTROINTESTINAL ANGIODYSPLASIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; PEPTIC ULCER BLEEDING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RISK FACTOR;

AGED; ANGIODYSPLASIA; BLOOD COAGULATION DISORDERS; BLOOD SPECIMEN COLLECTION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 14844323117     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200502000-00011     Document Type: Article

References (31)

1. Foutch GP. Angiodysplasia of the gastrointestinal tract. Am J Gastroenterol 1993; 88:807-818.
2. Okamura T, Kanaji T, Osaki K, Kuroiwa M, Yamashita S, Niho Y. Gastrointestinal angiodysplasia in congenital platelet dysfunction. Int J Hematol 1996; 65:79-84.
3. Ramsay D, Buist T, Macleod D, Heading R. Persistent gastrointestinal bleeding due to angiodysplasia of the gut in von Willebrand's disease. Lancet 1976; ii:275-278.
4. Alhumood SA, Devine DV, Lawson L, Nantel SH, Carter CJ. Idiopathic immune-mediated acquired von Willebrand's disease in a patient with angiodysplasia: demonstration of an unusual inhibitor causing a functional defect and rapid clearance of von Willebrand factor. Am J Hematol 1999; 60:151-157.
5. Saba HI, Morelli GA, Logrono LA. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 330:1789-1790.
6. Vujkovac B, Lavre J, Sabovic M. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient. Am J Kidney Dis 1998; 31:536-538.
7. Howard O, Buchanan J, Hunt R. Angiodysplasia of the colon. Lancet 1982; ii:16-19.
8. Boley SJ, Sprayregen S, Sammartano RJ, Adams A, Kleinhaus S. The pathophysiological basis for the angiographic signs of vascular ectasias of the colon. Radiology 1977; 125:615-621.
9. Gostout CJ, Bowie EJW, Balm R, Fischer PK. Is angiodysplasia associated with von Willebrand's disease? Gastroenterology 1990; 98:172L.
10. Veyradier A, Balian A, Wolf M, Giraud V, Montembault S, Obert B, et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120:346-353.
11. Bowie EJW. The role of von Willebrand in thrombosis. In: Poller L, Thomson JM (eds): Thrombosis and its Management. London: Churchill Livingstone; 1993. pp. 134-140.
12. Heer M, Sulser H, Hany A. Angiodysplasia of the colon: an expression of occlusive vascular disease. Hepatogastroenterology 1987; 34:127-131.
13. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-845.
14. Brock TA, Dvorak HF, Senger DR. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991; 138:213-221.
15. Shovlin C. Molecular defects in rare bleeding disorders: hereditary hemorrhagic telangiectasia. Thromb Hemost 1997; 78:145-150.
16. Blomback M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res 1988; 49:111-121.
17. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal haemorrhage in patients with advanced cirrhosis. Hepatology 1992; 15:672-676.
18. Dzik W, Arkin C, Jenkins R, Stump D. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood 1998; 71:1090-1095.
19. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thromboasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986; 68:275-280.
20. Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79:1749-1755.
21. Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med 1988; 318:1585-1595.
22. De Clerk F, Laung WE. Cooperation between matrix metalloproteinases and the plasminogen activator plasmin in tumor progression. Enzyme Protein 1996; 49:72-84.
23. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998; 83:832-840.
24. Junquera F, Saperas E, Torres I, Vidal T, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94:1070-1076.
25. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181:902-906.
26. Ostermann H, Tschope D, Greber W, Meyer-Rusenberg HW, van de Loo J. Enhancement of spontaneous fibrinolytic activity in diabetic retinopathy. Thromb Haemost 1992; 68:400-403.
27. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
28. Shatos MA, Doherty JM, Penar PL, Sobel BE. Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Circulation 1996; 94:636-642.
29. Marder VJ. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am J Med 1987; 83:15-19.
30. Al-Mohana JM, Lowe GD, Murray GD, Burns HG. Association of fibrinolytic tests with outcome of acute upper-gastrointestinal tract bleeding. Lancet 1993; 341:518-521.
31. Violi F, Ferro D, Quintarelli C, Alessandri C, Cordova C, CALC Group. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. Thromb Haemost 1996; 76:177-183.